Abstract
Highly active antiretroviral therapy (HAART) and direct acting antiviral agents (DAAs) are key elements in the effective pharmacotherapy of human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) respectively. These two chronic illnesses affect millions of persons at any given time, though only a select proportion has been eligible for successful treatment. With the development of newer, safer and more effective antiviral therapies it is expected that a greater proportion of those infected will have access to these life-saving therapies. However, it is also important to appreciate that this very population will also be subject to increased toxicities from these agents. In this review we outline the published nephrotoxic effects of select new agents used in the management of HIV and HCV, specifically commenting, where possible, on the role of epithelial organic transporters in explaining the said renal toxicities.
Keywords: Antiviral therapy, HCV, HIV, renal.
Current Drug Metabolism
Title:The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C
Volume: 16 Issue: 4
Author(s): Donald Mitema and Mohamed G. Atta
Affiliation:
Keywords: Antiviral therapy, HCV, HIV, renal.
Abstract: Highly active antiretroviral therapy (HAART) and direct acting antiviral agents (DAAs) are key elements in the effective pharmacotherapy of human immunodeficiency virus (HIV) and Hepatitis C virus (HCV) respectively. These two chronic illnesses affect millions of persons at any given time, though only a select proportion has been eligible for successful treatment. With the development of newer, safer and more effective antiviral therapies it is expected that a greater proportion of those infected will have access to these life-saving therapies. However, it is also important to appreciate that this very population will also be subject to increased toxicities from these agents. In this review we outline the published nephrotoxic effects of select new agents used in the management of HIV and HCV, specifically commenting, where possible, on the role of epithelial organic transporters in explaining the said renal toxicities.
Export Options
About this article
Cite this article as:
Mitema Donald and Atta G. Mohamed, The Role of Organic Transporters in Pharmacokinetics and Nephrotoxicity of Newer Antiviral Therapies for HIV and Hepatitis C, Current Drug Metabolism 2015; 16 (4) . https://dx.doi.org/10.2174/138920021604150902181109
DOI https://dx.doi.org/10.2174/138920021604150902181109 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determining the Relative Gene Expression Level of Hypoxia Related Genes in Different Cancer Cell Lines
Current Molecular Pharmacology The Combination of New Immunotherapy and Radiotherapy: A N ew Potential Treatment for Locally Advanced Non-Small Cell Lung Cancer
Current Clinical Pharmacology Insights into Nano-Photo-Thermal Therapy of Cancer: The Kinetics of Cell Death and Effect on Cell Cycle
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Perineural Invasion in Adenoid Cystic Carcinoma of the Salivary Glands: Anatomical Influences on Oncological Management
Current Cancer Therapy Reviews Osthole: A Multifunctional Natural Compound with Potential Anticancer, Antioxidant and Anti-inflammatory Activities
Mini-Reviews in Medicinal Chemistry A Better Platinum-Based Anticancer Drug Yet to Come?
Anti-Cancer Agents in Medicinal Chemistry Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Some Implications of Receptor Kinase Signaling Pathway for Development of Multitargeted Kinase Inhibitors
Current Radiopharmaceuticals Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Promising Targets in Anti-cancer Drug Development: Recent Updates
Current Medicinal Chemistry Flavonoids as Sirtuin Modulators
Current Topics in Medicinal Chemistry Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
Current Cancer Drug Targets Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Current Drug Targets A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews Hepatic Diseases Related to Triglyceride Metabolism
Mini-Reviews in Medicinal Chemistry MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers
Current Pharmaceutical Design Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Repositioning of RdRp Inhibitors Against HCV NS5B Polymerase Utilizing Structure-Based Molecular Docking
Combinatorial Chemistry & High Throughput Screening